Article Text
Statistics from Altmetric.com
We write to raise some of a number of serious concerns about the recent paper ‘Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal’.1 We believe that it is written in a misleading fashion and contains important errors of fact, presentation and inference.
Tabulated data for symptoms, reliever use and exacerbations are presented only for patients randomly assigned to SMART. The lead author had access to the analysis by Bateman et al2 that included full comparative data, as he wrote an accompanying editorial3 and cited it …
Footnotes
Competing interests MJP has received honoraria for participation on advisory boards and for CME presentations from AstraZeneca and GlaxoSmithKline. The quantum of involvement is significantly greater for AstraZeneca. CRJ has received honoraria for participation on advisory boards and for CME presentations from AstraZeneca, GlaxoSmithKline, Novartis, Bayer and Nycomed.
Provenance and peer review Not commissioned; not externally peer reviewed.
Linked Articles
- PostScript
- PostScript
- PostScript
- PostScript
- Airwaves